Replicel Life Sciences Inc REPCF

Primary Symbol: V.RP

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Buyout

<< Previous

Bullboard Posts

Next >>

Comment by RPINVESTOR1on Mar 28, 2024 12:08pm

90 Views

Post# 35958198

RE:Buyout

Ingiboy:-

The present offer to purchase would give shareholders a maximum of $0.16 USD per share (1 share x 8% x $2.00 USD). Shiseido - if interested - could offer say $0.25 USD per share. Would the CEO then use the 'poison pill' or some other strategy to benefit himself?

Also, if Shiseido does not make an offer soon I think that we can conclude that they were not too impressed with the RCH-01 Phase 2B Trial results.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec